QuidelOrtho Corp has initiated a significant restructuring plan that aims to enhance its operational efficiency and streamline its business focus. The company announced this development on November 3, 2026, alongside its third-quarter financial results. The restructuring includes appointing new leaders for its Core Diagnostics and Point of Care Diagnostics divisions while eliminating the Chief Operations Officer role.

As part of the restructuring, Jonathan Siegrist, PhD, has been appointed as the Head of Point of Care Diagnostics, and Bryan Hanson will serve as the Head of Core Diagnostics. Both appointees were previously in executive roles within the company, with Dr. Siegrist serving as the Executive Vice President of Research & Development and Chief Technology Officer, and Mr. Hanson as the Executive Vice President of Global Portfolio Management and Marketing.

The restructuring plan is designed to evolve QuidelOrtho's operating model and is expected to deliver over $80 million in annual savings starting in 2027. The company aims to improve its cost structure and better position itself in the competitive diagnostics market.

QuidelOrtho Corporation, incorporated in Delaware, operates within the In Vitro & In Vivo Diagnostic Substances industry. The company trades on the Nasdaq under the ticker symbol QDEL. Its recent filings include a Form 4 on October 19, 2026, and a Schedule 13G/A on October 7, 2026.

In the same filing, QuidelOrtho reported its financial results for the third quarter ended September 27, 2026. The company experienced a total revenue of $619 million, marking a 12% decrease compared to the prior year. However, excluding certain segments, total revenue showed a growth of 2% as reported.

The restructuring plan also involves the termination of Phil McLellan as Chief Operations Officer, effective November 9, 2026. McLellan will receive severance and other benefits as outlined in his Severance and Change in Control Agreement.

Looking ahead, QuidelOrtho is expected to file additional details regarding the restructuring and its impact on the company's operations in its upcoming Annual Report on Form 10-K for the fiscal year 2026.